Introducing Nordic RheumaTrace™: a breakthrough biomarker panel for rheumatic diseases. Backed by three decades of research and over 200 peer-reviewed publications, this panel features seven carefully selected biomarkers.

These biomarkers delve into the complexities of connective tissue degradation and immune cell dynamics, providing invaluable insights for researchers and drug developers. By pinpointing the disease pathway and determining the optimal dosage for positive outcomes, our panel is at the forefront of precision medicine in rheumatology.

The RheumaTrace™ biomarker panel for rheumatological diseases (RMDs) has been developed based on 3 decades of research and more than 200 peer-reviewed publications.

The panel comprises seven distinct biomarkers, carefully selected to encompass the intricacies of connective tissue degradation and immune cell dynamics. Together, these biomarkers offer researchers and drug developers invaluable insights into disease activity, the trajectory of disease progression, and the efficacy of therapeutic interventions.


By accurately identifying the critical pathway of the disease and the optimal dosage required to elicit a positive response, our panel represents a cutting-edge solution for precision medicine in rheumatology.

Elevate your research with RheumaTrace™ today!

Biomarkers in the RheumaTrace™ panel


The biomarkers in RheumaTrace are directly linked to the critical path of the disease and respond rapidly - within days and weeks - to effective drug intervention.

With a dose-dependent effect, the panel demonstrates that only efficacious doses of the drug reach clinically significant suppression, ultimately translating into a positive drug response.

As such, our panel has proven to be a valuable tool for dose-finding and efficacy prediction in phase I/II interventional trials, as well as insight into mode-of-mechanism in phase II/III.

The panel is likewise suitable for assessing and comparing drug response in head-to-head studies.

RheumaTrace™ shows pharmacodynamics and MoA

RheumaTrace™ enables targeted patient identification

As a smart translational medicine tool, RheumaTrace™ provides valuable support for drug (re)positioning efforts. By including connective tissue destruction markers, which have been shown to be elevated in various inflammatory and autoimmune conditions, the panel enables targeted patient identification for drug trials and therapy.

Conversely, the absence of such markers in non-inflammatory conditions further enhances the panel's specificity. With the ability to accurately identify patient populations likely to respond to specific drugs, our panel represents a cutting-edge solution for personalized medicine in rheumatology.

  • The joint tissue is a complex structure composed of various connective tissues that collectively provide support for function, stability, and maintenance.
  • Nordic Bioscience's biomarker technology enables direct measurement of these tissue fragments in blood, providing a precise and reliable assessment of tissue inflammation and disease activity in RMDs.
  • In rheumatological disorders (RMDs), homeostasis is disrupted by chronic inflammation, resulting in tissue destruction and the release of tissue fragments, particularly collagen fragments, into the bloodstream.
  • As these fragments are integral to the pathogenesis of RMDs and located on the critical path of any disease-modifying drug, our technology offers a valuable tool for guiding dose-finding and drug efficacy in drug development, and ultimately treatment decisions and monitoring patient outcomes.

Research questions answered by the RheumaTrace™ biomarkers


What impact does the compound have on bone inflammation and connective tissue degradation as indicated by C1M levels?

How does the compound influence inflammation and destruction of soft tissues, such as the synovium, as reflected by C3M measurements?

What effects does the compound have on the disruption of epithelial and endothelial tissues, as indicated by C4M levels?

Does the compound exhibit protective effects against cartilage loss and joint space narrowing, thus preserving joint integrity, reflected by C2M?

To what extent does the compound affect macrophage activity as indicated by VICM levels?

How does the compound influence T-cell activity, as reflected by C4G measurements?

What impact does the compound have on neutrophil activity as indicated by CPa9-HNE levels?

Further questions about RheumaTrace™? Get in touch with us!

Download the RheumaTrace™Supporting Documentation

Nordic Bioscience's assays and services are research use only products and services and do not qualify for medical or diagnostic purposes.

Please don't hesitate to contact us if you have any questions or other inquiries.

Are you interested in learning more about Nordic Bioscience?
Enter your information in the form and a representative will contact you shortly.

By submitting this form you agree to our terms and conditions.